MX2024001962A - Vectores de citomegalovirus humano (hcmv) recombinante y usos de estos. - Google Patents
Vectores de citomegalovirus humano (hcmv) recombinante y usos de estos.Info
- Publication number
- MX2024001962A MX2024001962A MX2024001962A MX2024001962A MX2024001962A MX 2024001962 A MX2024001962 A MX 2024001962A MX 2024001962 A MX2024001962 A MX 2024001962A MX 2024001962 A MX2024001962 A MX 2024001962A MX 2024001962 A MX2024001962 A MX 2024001962A
- Authority
- MX
- Mexico
- Prior art keywords
- hcmv
- vectors
- human cytomegalovirus
- recombinant human
- disclosure relates
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 4
- 239000013598 vector Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239298P | 2021-08-31 | 2021-08-31 | |
| US202263356386P | 2022-06-28 | 2022-06-28 | |
| PCT/US2022/075670 WO2023034801A1 (en) | 2021-08-31 | 2022-08-30 | Recombinant hcmv vectors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001962A true MX2024001962A (es) | 2024-03-01 |
Family
ID=83447741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001962A MX2024001962A (es) | 2021-08-31 | 2022-08-30 | Vectores de citomegalovirus humano (hcmv) recombinante y usos de estos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240384296A1 (enExample) |
| EP (1) | EP4395809A1 (enExample) |
| JP (1) | JP2024534189A (enExample) |
| KR (1) | KR20240049807A (enExample) |
| AU (1) | AU2022339765A1 (enExample) |
| CA (1) | CA3226699A1 (enExample) |
| CL (1) | CL2024000580A1 (enExample) |
| CO (1) | CO2024001513A2 (enExample) |
| IL (1) | IL310663A (enExample) |
| MX (1) | MX2024001962A (enExample) |
| TW (1) | TW202311531A (enExample) |
| WO (1) | WO2023034801A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024059635A2 (en) * | 2022-09-13 | 2024-03-21 | Oregon Health And Science University | Universal t cell-based, cmv-vectored vaccine for influenza |
| EP4694922A1 (en) * | 2023-04-14 | 2026-02-18 | BioNTech SE | Hiv vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| NZ728208A (en) * | 2014-07-16 | 2018-07-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EA201791806A1 (ru) | 2015-02-10 | 2017-12-29 | Орегон Хелс Энд Сайенс Юниверсити | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов |
| US10688164B2 (en) * | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| WO2018075591A1 (en) * | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| CA3148642A1 (en) * | 2019-08-20 | 2021-02-25 | Klaus J. FRUEH | Modulation of t cell responses by ul18 of human cytomegalovirus |
-
2022
- 2022-08-30 US US18/687,050 patent/US20240384296A1/en active Pending
- 2022-08-30 EP EP22777537.6A patent/EP4395809A1/en active Pending
- 2022-08-30 IL IL310663A patent/IL310663A/en unknown
- 2022-08-30 MX MX2024001962A patent/MX2024001962A/es unknown
- 2022-08-30 KR KR1020247006599A patent/KR20240049807A/ko active Pending
- 2022-08-30 WO PCT/US2022/075670 patent/WO2023034801A1/en not_active Ceased
- 2022-08-30 TW TW111132771A patent/TW202311531A/zh unknown
- 2022-08-30 JP JP2024513410A patent/JP2024534189A/ja active Pending
- 2022-08-30 AU AU2022339765A patent/AU2022339765A1/en active Pending
- 2022-08-30 CA CA3226699A patent/CA3226699A1/en active Pending
-
2024
- 2024-02-13 CO CONC2024/0001513A patent/CO2024001513A2/es unknown
- 2024-02-26 CL CL2024000580A patent/CL2024000580A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4395809A1 (en) | 2024-07-10 |
| IL310663A (en) | 2024-04-01 |
| CO2024001513A2 (es) | 2024-03-07 |
| TW202311531A (zh) | 2023-03-16 |
| JP2024534189A (ja) | 2024-09-18 |
| US20240384296A1 (en) | 2024-11-21 |
| KR20240049807A (ko) | 2024-04-17 |
| CL2024000580A1 (es) | 2024-09-06 |
| WO2023034801A1 (en) | 2023-03-09 |
| AU2022339765A1 (en) | 2024-01-25 |
| CA3226699A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| MX380631B (es) | Vectores de adenovirus canino | |
| MX2020007675A (es) | Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante. | |
| AU2019349036A8 (en) | Immune composition, preparation method therefor, and application thereof | |
| MX2020008394A (es) | Tratamiento que usa arn que codifica citoquinas. | |
| CL2024000580A1 (es) | Vectores de hcmv recombinante y usos de estos | |
| BR112015022617A2 (pt) | polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| HRP20240163T1 (hr) | Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom | |
| MX2022002315A (es) | Anticuerpos anti-cd96 y sus metodos de uso. | |
| WO2019028396A8 (en) | Induction of protective immunity against antigens | |
| MX2019014674A (es) | Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones. | |
| CO2022004470A2 (es) | Vectores de herpesvirus de los pavos recombinante que expresan antígenos de patógenos aviares y usos de estos | |
| EA201890042A1 (ru) | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
| ZA202003070B (en) | Lassa vaccine | |
| MX2022005535A (es) | Composiciones y metodos para inmunoterapia. | |
| EA200970731A1 (ru) | Рекомбинантные антигены цитомегаловируса человека (hcmv) | |
| PH12021553186A1 (en) | Chikungunya vaccine formulations | |
| MX2017012389A (es) | Vacuna del virus de la parotiditis recombinante jeryl lynn2. | |
| PH12020551357A1 (en) | Expression of pneumococcal surface protein a (pspa) | |
| MX2019006244A (es) | Construcciones de vectores virales para la expresion de adyuvantes geneticos que activan la ruta sting. | |
| WO2021076755A8 (en) | An activity-guided map of electrophile-cysteine interactions in primary human immune cells | |
| MX374380B (es) | Composicion inmunógena de clostridium difficile. | |
| EA202092164A1 (ru) | Новый ehv с инактивированным ul18 и/или ul8 | |
| WO2019106432A3 (en) | Viral vector constructs for expression of genetic adjuvants mimicking cd40 signaling |